• 1
    Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998; 34: 18571864.
  • 2
    Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34: 730751.
  • 3
    Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31: 12501256.
  • 4
    Schiel X, Hebart H, Kern WV, et al. Sepsis in neutropenia: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003; 82(Suppl 2): S158S166.
  • 5
    Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003; 36: 11031110.
  • 6
    Lyman GH. Guidelines of the National Comprehensive Cancer Center Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Cancer Netw. 2005; 3: 557571.
  • 7
    Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003; 44: 20692076.
  • 8
    Lyman GH, Dale D, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004; 22: 43024311.
  • 9
    Schuette HL, Tucker TC, Brown ML, et al. The costs of cancer care in the United States: implications for action. Oncology (Huntingt). 1995; 9(Suppl 11): S19S22.
  • 10
    Dale DC, McCarter GC, Crawford J, et al. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Cancer Netw. 2003; 1: 440454.
  • 11
    Brown F. Uniform hospital discharge data set. In: ICD-9CM coding handbook with answers. Chicago: American Hospital Association Press, Health Forum, 2005: 1924.
  • 12
    Buck CJ. ICD-9-CM official guidelines for coding and reporting. In: 2005 ICD-9-CM and HCPCS. Philadelphia: Saunders, 2005: 329.
  • 13
    Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005; 103: 19161924.
  • 14
    Basu SK, Fernandez ED, Fisher SG, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005; 23: 79587966.
  • 15
    Clark OA, Lyman G, Castro AA, et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev. 2003;(3):CD003039.
  • 16
    Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988; 148: 25612568.
  • 17
    Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992; 10: 316322.
  • 18
    Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18: 30383051
  • 19
    Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis. 1999; 18: 539544.
  • 20
    Malik I, Hussain M, Yousuf H. Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. J Infect. 2001; 42: 120125.
  • 21
    Darmon M, Azoulay E, Alberti C, et al. Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med. 2002; 28: 17751780.
  • 22
    Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997; 25: 247259.
  • 23
    Carratala J, Roson B, Fernandez-Sevilla A, et al. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med. 1998; 158: 868872.
  • 24
    Rossini F. Prognosis of infections in elderly patients with haematological diseases. Support Care Cancer. 1996; 4: 4650.
  • 25
    Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis. 1996; 15: 291296.
  • 26
    Ravaud A, Chevreau C, Laurent C, et al. Granulocyte-macrophage colony stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol. 1998; 16: 29302936.
  • 27
    Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med. 1994; 121: 492501.
  • 28
    Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001; 93: 3138.
  • 29
    Anaissie EJ, Vartivarian S, Bodey GP, et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor in cancer patients with fever and neutropenia. Am J Med. 1996; 100: 1723.
  • 30
    Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematologic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst. 1993; 85: 488493.